Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $40.88 Average Price Target from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average rating of “Hold” by the ten research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $40.8750.

Several equities research analysts have recently commented on the company. Citigroup upped their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. HC Wainwright boosted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada upped their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. reduced their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Finally, Truist Financial lowered their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st.

Agios Pharmaceuticals Stock Up 0.3%

Shares of AGIO stock opened at $31.70 on Monday. The stock’s 50-day moving average price is $34.66 and its 200 day moving average price is $30.97. The stock has a market capitalization of $1.89 billion, a PE ratio of -4.52 and a beta of 0.58. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Analysts expect that Agios Pharmaceuticals will post -6.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AGIO. Wellington Management Group LLP boosted its stake in shares of Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter worth $35,478,000. State Street Corp raised its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares in the last quarter. TCG Crossover Management LLC lifted its holdings in Agios Pharmaceuticals by 105.2% in the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares during the period. Finally, Capital International Investors acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at $19,159,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.